NCT00313911View on ClinicalTrials.gov

Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.

PHASE3CompletedINTERVENTIONAL

Enrollment

2,133

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

January 31, 2008

Study Completion Date

February 29, 2008

Conditions

DiphtheriaTetanusPertussisHaemophilus Influenzae Type bHepatitis B

Interventions

BIOLOGICAL

DTaP-IPV-HB-PRP~T

0.5 mL, Intramuscular (IM)

BIOLOGICAL

Tritanrix-HepB/Hib

0.5 mL, Intramuscular

Trial Locations (2)

Unknown

Mexico City

Lima

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00313911 - Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months. | Biotech Hunter | Biotech Hunter